Daily14h
Kidney Function Decline Identified as Key Mortality Risk Marker in Transthyretin Amyloid Cardiomyopathy: JAMA
UK: A recent retrospective cohort study has highlighted the critical role of kidney function in patients diagnosed with ...
STAT12h
BridgeBio wins FDA approval for heart disease drug
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the condition in over five years and ...
HC Wainwright Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $49.00
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...
44,623 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Purchased by Intech Investment Management LLC
Intech Investment Management LLC acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd ...
Alnylam Pharmaceuticals: Promising Advancements in Alzheimer’s Treatment with RNA Interference Therapeutics
Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...
J.P. Morgan Remains a Hold on Alnylam Pharma (ALNY)
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), with a price ...